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RESEARCH ARTICLE
Genotype, Extrapyramidal Features, and
Severity of Variant Ataxia-Telangiectasia
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Objective: Variant ataxia-telangiectasia is caused by mutations that allow some retained ataxia telangiectasia-mutated
(ATM) kinase activity. Here, we describe the clinical features of the largest established cohort of individuals with variant
ataxia-telangiectasia and explore genotype-phenotype correlations.
Methods: Cross-sectional data were collected retrospectively. Patients were classiﬁed as variant ataxia-telangiectasia
based on retained ATM kinase activity.
Results: The study includes 57 individuals. Mean age at assessment was 37.5 years. Most had their ﬁrst symptoms
by age 10 (81%). There was a diagnostic delay of more than 10 years in 68% and more than 20 years in one third of
probands. Disease severity was mild in one third of patients, and 43% were still ambulant 20 years after disease
onset. Only one third had predominant ataxia, and 18% had a pure extrapyramidal presentation. Individuals with
extrapyramidal presentations had milder neurological disease severity. There were no signiﬁcant respiratory or
immunological complications, but 25% of individuals had a history of malignancy. Missense mutations were associ-
ated with milder neurological disease severity, but with a higher risk of malignancy, compared to leaky splice site
mutations.
Interpretation: Individuals with variant ataxia-telangiectasia require malignancy surveillance and tailored management.
However, our data suggest the condition may sometimes be mis- or underdiagnosed because of atypical features,
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including exclusive extrapyramidal symptoms, normal eye movements, and normal alpha-fetoprotein levels in some
individuals. Missense mutations are associated with milder neurological presentations, but a particularly high malig-
nancy risk, and it is important for clinicians to be aware of these phenotypes.
ANN NEUROL 2019;85:170–180
Ataxia-telangiectasia is a rare autosomal-recessive disordercaused by mutations in the ATM gene on chromosome
11q22.3 (MIM 208900).1 The ataxia telangiectasia-mutated
(ATM) protein is a serine-threonine protein kinase, which
phosphorylates more than 700 substrates and is a key player
in the cellular response to double-stranded DNA damage.2
The clinical and genetic features of ataxia-telangiectasia vary,
and two forms of the disease have been described.
Classic (or typical) ataxia-telangiectasia presents
with a severe phenotype and has an estimated incidence
of 1 in 300,000.3 Individuals with classic ataxia-
telangiectasia have absent ATM kinase activity,4 either
attributed to two null mutations or mutations which
result in protein without ATM kinase activity. It is a
multisystem neurodegenerative disease which also causes
immunological defects, respiratory problems, oculocuta-
neous telangiectasia, and an increased risk of malig-
nancy.5,6 Affected children are usually wheelchair bound
before teenage years and have severe neurological disabil-
ity, including cerebellar ataxia, extrapyramidal features,
oculomotor dyspraxia, and polyneuropathy.7 Most indi-
viduals with classic ataxia-telangiectasia die before the
age of 30; malignancy or respiratory failure are the main
causes of death.8,9
In addition to classic ataxia-telangiectasia a second
form, variant ataxia-telangiectasia has been described as a
cause of neurological dysfunction.10,11 A study of 51 patients
with ataxia-telangiectasia (including 9 with retained ATM
kinase activity) showed that individuals with retained ATM
kinase activity have a milder neurological phenotype.4 Vari-
ant ataxia-telangiectasia results either from leaky splice site
mutations which allow expression of some normal ATM
protein or missense mutations which produce a mutant
ATM protein with activity.12 It has been speculated that the
presence of some ATM kinase activity relates to a milder
neurological phenotype and a lower risk of systemic compli-
cations. Furthermore, a range of atypical neurological pre-
sentations have been reported to occur in some individuals
with variant ataxia-telangiectasia.
Previously published reports of variant ataxia-
telangiectasia are limited to small cohorts of less than
15 individuals7,13–16 or case studies of unusual
presentations.17–21
The true clinical spectrum of variant ataxia-
telangiectasia is unknown, and it is not clear which factors
determine the extreme clinical variability that has been
reported. It is unclear whether affected individuals require
speciﬁc surveillance for systemic complications and malig-
nancy, similar to existing management recommendations
of classic ataxia-telangiectasia.22,23
Here, we report the clinical features of the largest
established cohort of patients with variant ataxia-telangiec-
tasia. We provide prognostic information and explore
genotype-phenotype correlations to inform management
guidelines.
Patients and Methods
Probands
Clinical data were retrospectively collected from case notes
for all individuals with variant ataxia-telangiectasia who have
attended the National Adult Ataxia-Telangiectasia service
(Papworth Hospital, UK), the Ataxia-Telangiectasia Special-
ist Centre (Nottingham City Hospital, UK), and the Excel-
lence Centre of Movement Disorders (Radboud UMC,
Nijmegen, Netherlands). Analysis includes single cross-
sectional data using the most recent recorded clinical
assessment.
Molecular Genetics Studies
Patients were classiﬁed as having variant ataxia-
telangiectasia based on retained ATM kinase activity.
Patients with a mutation in the initiator methionine
codon were included because of some uncertainty of
ATM activity associated with these mutations. ATM
mutations were identiﬁed by Sanger sequencing of PCR-
ampliﬁed ATM exon sequences. A lymphoblastoid cell
line was derived from each patient’s blood, and immuno-
blotting for ATM expression and ATM activity assays
were performed using methods as previously described.24
Chromosomal radiosensitivity was measured following
exposure to 1Gy of gamma rays at cell cycle phase G2.
Neurological Assessment
Clinical neurological assessment was performed by a neu-
rologist with a special interest in ataxia-telangiectasia. The
Scale for Assessment and Rating of Ataxia (SARA)25 and
Ataxia-Telangiectasia Neurological Examination Scale
Toolkit (A-T NEST) scores11 were recorded. As part of
the neurological examination, a subjective assessment of
eye movement abnormalities was recorded by the examin-
ing neurologist as normal eye movements, mildly abnor-
mal eye movements (including nystagmus, slowing of
saccades, and mild oculomotor dyspraxia), or severely
February 2019 171
Schon et al.: Variant Ataxia-Telangiectasia
abnormal eye movements (including marked oculomotor
apraxia).
Neurological Phenotype
Individuals were categorized into three neurological phe-
notypic groups to reﬂect those neurological symptoms,
which have been reported to most commonly occur in
variant ataxia-telangiectasia:
Group A: Cerebellar ataxia and/or peripheral neu-
ropathy with minimal or no extrapyramidal involvement
Group B: Cerebellar ataxia and/or neuropathy plus
additional extrapyramidal features
Group C: Extrapyramidal signs without signiﬁcant
ataxia and/or peripheral neuropathy
Cross-sectional Clinical Neurological Disease
Severity
An overall assessment of current severity was made using
level of mobility and self-care.
Mild: Individuals still ambulant with/without a
walking aid and could use the upper limbs for most activi-
ties without help. A-T NEST scores within this group
were > 55, SARA scores <22.
Moderate: Individuals used a wheelchair frequently,
but were able to transfer, walk a few steps with help, and
use the upper limbs for most activities, such as feeding
themselves. A-T NEST scores within the moderate group
were 42 to 75, SARA scores 15 to 33.
Severe: Individuals were permanently wheelchair
bound, were unable to transfer unaided, and had signiﬁ-
cant limitation of upper limb function, requiring assis-
tance with most activities of daily living. A-T NEST
scores within this group were < 46, SARA scores >30.
Neurological Investigations
Results of nerve conduction studies and electromyogram
(EMG) were reviewed. Neuropathy was graded depending
on the severity of the nerve conduction abnormality and
of any accompanying EMG impairment. The neuropathy
grade was determined by amplitude measures and how
widespread the abnormalities were. For example, in the
case of the sensory changes:
• impairment of sural amplitude only: mild
• absent sural responses: mild-moderate
• impaired upper limb digital potential and absent sural
responses: moderate
• impaired/absent upper limb potential and impaired
radial amplitude: moderate-severe
• absent sensory responses in upper limb and lower limb:
severe.
A similar approach was adopted for motor potentials.
If nerve conduction studies were relatively preserved, while
EMG abnormality was detected, then the subcategorization
of a suspected motor neuronopathy was documented.
MRI brain scans were conducted to rate atrophy of
the cerebellar vermis and hemispheres on sagittal three-
dimensional T1-weighted sequence. Cerebellar atrophy
was assessed separately for the vermis and jointly for both
hemispheres and rated as absent, mild (mild widening of
sulci and ﬁssures, normal size of folia), moderate (moder-
ate widening of sulci and ﬁssures associated with volume
loss of folia), or severe (marked widening of sulci and ﬁs-
sures with marked volume loss of folia). White matter
hyperintensities on ﬂuid-attenuated inversion recovery
sequence were classiﬁed as punctate, beginning conﬂuent
or conﬂuent.26 Cerebral microbleeds were assessed on
susceptibility-weighted imaging (SWI) or T2*W-gradient
echo sequence.27
RESPIRATORY ASSESSMENT. Patients attending Papworth
were assessed by a consultant respiratory physician. They
underwent arterial blood gas measurement, pulmonary
function testing, overnight oximetry and low dose com-
puted tomography (CT) thorax. Five of the Dutch
patients had spirometry.
IMMUNOLOGICAL ASSESSMENT. Immunological investi-
gations included immunoglobulin levels (immunoglobulin
IgG, IgA, IgM, IgG2, and IgE), serum electrophoresis if
indicated, lymphocyte subset analysis, and assessment of
serum antibody to pneumococcus, tetanus, and haemophi-
lus vaccine. History of immunizations, infections, and
treatment was recorded.
General Assessment
Past medical history, including diabetes and malignancy,
was documented in all patients. Level of mobility and age
at ﬁrst wheelchair use were recorded. Examination for
conjunctival telangiectasia, measurement of weight,
height, and body mass index (BMI), blood tests for alpha-
fetoprotein (AFP), and liver function tests (LFTs) and
liver ultrasound scan were carried out in the majority of
patients, but this was not standardized between centres.
Ethical Considerations
The study was approved by the Health Research
Authority.
Statistical Analysis
In order to test the effect of the genetic covariates (pres-
ence of a missense mutation with retained ATM kinase
activity, number of mild mutations, ATM protein levels,
and chromosomal radiosensitivity) on neurological and
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other clinical features, we corrected the regression models
for ﬁxed (age, sex, and age of onset) and random effects
(hospitals and families). We tested the effect of each genetic
covariate on quantile normalized SARA score, A-T NEST
score, age at ﬁrst wheelchair use, and AFP levels using a lin-
ear mixed-effects model (lmer function, R project lme4
package28). For peripheral neuropathy, conjunctival telangi-
ectasia, and malignancy, we used a generalized linear mixed-
effects model (glmer function, R project lme4 package28)
treating the response as a dichotomous variable. Associations
between the neurological group and each genetic covariate
were tested using a multinomial logistic regression (multi-
nom function, R project nnet package29) with hospitals and
families treated as ﬁxed effects. For overall severity and eye
movements responses, we used a mixed regression model for
ordinal data, the ordered regression model implemented in
the cmml function, R project ordinal package.30
Results
Demographic Features and Employment
The study included 57 individuals (23 males, 34 females)
from 50 families (Supplementary Table 1). Mean age was
37.5 years (standard deviation [SD], 12.3; range 11–58),
with 4 patients aged <18 years. Six women had offspring
(5 from the UK cohort, 1 from the Dutch cohort). None
of the men had offspring. Three individuals are deceased.
Eleven individuals were in employment, and 2 were stu-
dents. Seven had university degrees. Thirty-nine patients
were recruited from Papworth, 6 from Nottingham, and
12 from the Dutch cohort.
Neurological Features
ONSET, DURATION, MOBILITY, AND SEVERITY. Age of
onset is shown in Figure 1A. Most individuals (46 of 57) had
their ﬁrst symptoms by age 10 years. Individuals with disease
onset before 10 years were considered to have early-onset dis-
ease. Six had onset between 11 and 16 years. Five had adult
onset disease.
Disease duration at last assessment ranged from
10 to 54 years. Disease duration was 10 to 20 years in
16 individuals, 20 to 30 years in 13, and > 30 years in 28.
Age at diagnosis ranged from 2 to 47 years (Fig 1B).
The diagnosis was made within 1 year of symptom onset
in 7 individuals and in 1 to 9 years in 17. There was a
diagnostic delay of 10 to 20 years in 12 and > 20 years in
17 (not documented in 4).
Forty-two individuals used a wheelchair and 15 were
still ambulant. Median age at ﬁrst getting a wheelchair
was 20 years (range, 8–51; Fig 1C). Eleven individuals got
their ﬁrst wheelchair within 10 years of symptom onset,
17 in 10 to 20 years, and 14 after more than 20 years.
Seven individuals were currently ambulant after a disease
duration of 10 to 20 years and 8 after >20 years.
Seventeen individuals had mild disease, 26 had moder-
ate disease, and 10 had severe disease. Classiﬁcation of disease
severity was not available for 4 individuals. There was 1 outlier
in the severe group, a pediatric patient who used a wheelchair
since age 8, and had an A-T NEST score of 72.
FIGURE 1: Age at (A) symptom onset, (B) diagnosis with
ataxia-telangiectasia, and (C) ﬁrst using a wheelchair were
obtained from each individual’s clinical notes.
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NEUROLOGICAL PHENOTYPE. Three distinct patterns of
neurological deﬁcits were observed. The neurological fea-
tures and treatments in each group are summarised in
Supplementary Table 2.
Group A (Predominant Cerebellar Ataxia and/or
Peripheral Neuropathy With Minimal or no
Extrapyramidal Involvement). Nineteen individuals
(33%) were in Group A. Severe oculomotor dyspraxia was
common (11 of 19; 58%) and 6 patients had mild eye move-
ment abnormalities (32%). A 15-year-old with mild disease
had normal eye movements. The other patient with normal
eye movements presented initially with a severe reaction to
radiotherapy for breast cancer and had a mild phenotype con-
sisting of peripheral neuropathy with only minimal limb
ataxia.31 Disease severity was moderate or severe, except in
the individual described above and 2 pediatric patients aged
11 and 15 years. Mean disease duration was 32 years.
Group B (Disability Determined by a Mixture of Ataxia
and/or Peripheral Neuropathy Plus Additional
Extrapyramidal Features). Twenty-eight individuals
(49%) were in Group B. Their extrapyramidal features
included dystonic posturing/neck dystonia (12 patients),
dystonic tremor (11 individuals), choreiform movements
(9 patients), and orofacial dystonia (5 patients). Two
patients had a resting tremor. In this group, 12 of
28 (43%) exhibited prominent oculomotor dyspraxia,
43% had mildly abnormal eye movements, and 4 patients
had normal eye movements. Disease severity was widely
distributed. Six individuals had mild disease, 15 moderate
disease, and 4 individuals were severely affected (not docu-
mented in 3). Mean disease duration was 30 years.
Group C (predominantly extrapyramidal signs). Ten
individuals (18%) were in Group C. One individual
exhibited marked truncal dystonic spasms which limited
his ability to walk.32 Another patient had a clinical pheno-
type typical of myoclonic dystonia, which improved mark-
edly following deep brain stimulation.33 One individual
had marked orofacial dystonia, but otherwise an essentially
normal neurological examination with no limb ataxia or
dystonia.17 One exhibited neck and limb dystonia, which
was treated with botulinum toxin injections and another
had hemichorea. Three siblings presented with severe rest-
ing tremor (onset between 16 and 34 years) and anterior
horn neuronopathy.18 One individual presented with rest-
ing tremor at age 12 years and then developed chorea-
athetosis and dystonia. Another presented initially with
chorea-athetosis.
Two patients (20%) had marked oculomotor
dyspraxia, 2 had mildly abnormal eye movements,
and 6 of 10 of individuals had normal eye
movements. Disease severity was classiﬁed as mild in
8 of 10, and 6 individuals in this group were in
employment at the time of assessment. Mean disease
duration was 28 years.
NEUROLOGICAL INVESTIGATIONS. Neurophysiology.
Neurophysiology studies were performed in 34 individuals.
Eighteen had an axonal sensorimotor polyneuropathy of
varying severity. Three showed predominant involvement
of the motor neurons. Nine had an axonal sensorimotor
polyneuropathy with likely spinal muscular atrophy com-
ponent. Four had normal/nearly normal neurophysiology
studies.
Detailed neurophysiology results for 21 patients
assessed through Papworth are shown in Supplementary
Table 1.
Radiology. Brain MRI scans were available in a total of
35 individuals (including 23 performed through the Pap-
worth service, 10 Dutch individuals, and 2 patients
through the Nottingham clinic). Cerebellar atrophy was
found in 29 individuals. Six scans were reported as show-
ing a normal cerebellum (age, 19–46 years), of which one
also showed atrophy of the left corpus nucleus caudatus.
Seven individuals had white matter changes (single lesion
in 2, a few punctate lesions in 5). Cerebral microbleeds
were noted in 2 individuals. One had multiple, mainly in
the occipital subcortical white matter (age 53). The other
had a single microbleed in the right external capsule
(age 55).
Brain MRI scans performed through Papworth were
reviewed by a consultant radiologist. Cerebellar atrophy
was observed in 23 of 23 scans. Atrophy of the cerebellar
vermis was classiﬁed as mild in 8, moderate in 9, and
severe in 6. Atrophy of the cerebellar hemispheres was
classiﬁed as mild in 11, moderate in 7, and severe in
5 (Fig 2A–C).
Other Clinical Features
ENDOCRINE FUNCTION. Mean height percentile was
48.1 (SD, 31.1; 53 patients evaluated). Mean BMI was
23.3 (SD, 4.8; 49 patients evaluated). Six individuals were
underweight (BMI, <18.5), and 4 had gastrostomy feeding
because of dysphagia and/or poor appetite. Two patients
had type 2 diabetes. None had type 1 diabetes.
CONJUNCTIVAL TELANGIECTASIA. Conjunctival telangi-
ectasia was observed in 35 of 56 individuals with docu-
mented assessment (63%).
RESPIRATORY FUNCTION. No patient had severe lung
disease. CT thorax was performed in 39 patients. Thirty
showed normal results, 6 showed mild bronchiectasis,
174 Volume 85, No. 2
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1 showed mild emphysema (ex-smoker), 1 showed patchy
air trapping, and 1 showed two left upper lobe nodules
(likely intrapulmonary lymph nodes).
Arterial blood gases showed mean PaO2 12.4 kPa
(SD, 1.34) and PaCO2 5.17 kPa (SD, 0.52). Of 39 results,
only one was abnormal with mild hypoxemia. Overnight
oximetry in 37 subjects did not show hypoventilation,
with mean oxygen saturations of 96.4% (SD, 1.35) and
mean 4% desaturation index of 3.8 (SD 3.26). Pulmonary
function data from 42 individuals showed mean FEV1
80.2% (SD, 18.7), FVC 79.7% (SD, 21.6), and KCO
95.5% (SD, 19.3%). Twenty spirometries were restrictive;
however, patients struggled with spirometric technique.
IMMUNOLOGICAL FUNCTION. Infection history was
assessed in all patients and showed episodes of severe
chickenpox (2), sinusitis (1), recurrent boils (1), frequent
urinary tract infections (1), and sore throats 12 times per
FIGURE 2: (A) MRI scans showing examples of mild, moderate and severe cerebellar atrophy. The top row shows midline images
to assess vermian atrophy and the bottom row shows parasagittal images for assessing hemispheric atrophy. (B) MRI scans
showing examples of white matter lesions. (C) MRI scans showing microbleeds. MRI = magnetic resonance imaging.
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year (1). Two individuals were taking azithromycin pro-
phylaxis for lower respiratory tract infections. No individ-
uals were receiving immunoglobulin therapy.
Subtle signs of immune dysregulation and possible
immune deﬁciency were observed in a number of patients.
Immunoglobulin results were available in 52 patients. Poly-
clonal increases were observed in IgG (1), IgA (7), and IgM
(12). One further patient had increased IgG and IgA. Four
patients had a monoclonal gammopathy of unknown signiﬁ-
cance. One individual had mild panhypogammaglobulinemia.
A slight reduction in total IgG was observed in 1 and IgA in
5 individuals. One had IgA deﬁciency (<0.07 μg/ml). IgE
was below level of detection in 8 patients.
Lymphocyte subpopulation results were available
in 44 patients. Slight reductions in CD4 and CD8
counts were found in 2 and 12 patients, respectively,
and 16 patients had CD19 counts just below the normal
range.
AFP LEVELS. Mean serum AFP was 176 μg/l (range,
2–600; SD, 146) in 45 individuals with a result available.
Three (6.6%) had levels in the normal range
LIVER ULTRASOUND, LFTS. Liver ultrasound was per-
formed in 36 patients. Seven showed fatty liver and three
detected liver lesions (hemangioma, neuroendocrine tumour,
and metastatic prostate cancer). Fifteen of 44 patients with
LFT results available had mildly abnormal results.
Malignancy
Fourteen patients have been diagnosed with a malignancy.
Solid tumours included ﬁve female unilateral estrogen-
receptor positive breast cancers (age, 28–44 years), one der-
matoﬁbrosarcoma protuberans of the breast (age 29), one
neuroendocrine tumor (age 48), one pancreatic cancer (died
age 48), one pelvic mass (possible germ-cell tumor at age
11), and one prostate cancer (age 52). Lymphoid malignan-
cies included T-cell non-Hodgkin’s lymphoma (age 2),
acute lymphoblastic leukemia (age 9), chronic myeloid leu-
kemia (age 39), and chronic lymphoblastic leukemia (patient
also had breast cancer and died aged 47 years). One patient
died of acute lymphoblastic leukemia aged 51.
Genetics
FAMILY HISTORY. Nineteen individuals had a family his-
tory of ataxia-telangiectasia in a sibling, and 4 had affected
siblings who died from malignancies (primary hepatoma,
ectopic pituitary tumor, and 2 with lymphomas). There
was parental consanguinity in two families. Twenty of
114 parents had been diagnosed with a cancer (18%).
Mothers of 10 patients developed breast cancer (aged
39–64 years).
CYTOGENETIC FEATURES. Chromosomal radiosensitivity
was normal in 15 of 48 individuals tested (31%) and
raised in 33 of 48 (69%). Two had a high level, the same
as expected in classic ataxia-telangiectasia.
MUTATION ANALYSIS. Mutation analysis (Supplementary
Table 1) revealed mutations in 111 of 114 alleles. Patients
were classiﬁed based on the mutation present causing the
retained kinase activity.
Individuals in Genetic Group 1 all have a leaky
splice site mutation, which allows some normal ATM pro-
tein to be expressed with kinase activity. Fourteen patients
in this group have the c.5763-1050A > G mutation.
Individuals in Genetic Group 2 all have a missense
mutation, which results in the presence of a mutant pro-
tein with some ATM kinase activity.
Individuals in Genetic Group 3 have mutations
affecting the initiator methionine codon. These mutations
allow expression of a very low level of truncated protein.31
Patients with these mutations have been noted to have a
milder clinical course,24 and there is some uncertainty of
ATM activity associated with these mutations.
Individuals in Genetic Group 4 have one conﬁrmed
mutation and one mutation which has not been identiﬁed or
not been completely characterized. Patient 50 has a missense
mutation Val2716Ala which is associated with retained ATM
activity. The other 6 patients showed a low level of ATM pro-
tein and low level of ATM kinase activity. Complementary
DNA (cDNA) was examined in these cases. Two have alter-
ations found at the cDNA level, but no potentially causative
mutations found in genomic DNA. The mutations giving pro-
tein with activity are likely to be intronic splice site mutations.
Twelve patients (1, 2, 18a,b, 26, 31, 33, 35 and
37a-c, 41) had two “milder” mutations, which are both
known to be associated with retained ATM kinase activity.
GENOTYPE-PHENOTYPE CORRELATION. Cell lines from
51 of 51 patients tested showed retained expression of
some ATM protein. This ranged from just detectable
(~5%) to near normal.
ATM kinase activity was tested in cell lines from
45 patients. Cells derived from patients 34 and 42 showed
possibly a low level of ATM kinase activity.
The 4 patients (34, 42, 43, and 44) with absent or
possibly just detectable ATM kinase activity had more
severe disease. Onset of symptoms was between 1 and
2.5 years, with ﬁrst wheelchair use at 8 years in 2 patients
and 11 and 13 years in the other 2. Two have percutane-
ous endoscopic gastrostomy feeding tubes.
There are two major subgroups of variant patients:
those with a missense mutation producing some ATM pro-
tein with retained activity (Group 2, and 1 in Group 4) and
176 Volume 85, No. 2
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those with a leaky splice site mutation allowing expression
of a low level of normal ATM with some activity (Group
1, and most likely 6 in Group 4).
Individuals with at least one missense mutation which
produces a mutant protein with residual kinase activity had
milder neurological disease compared to the rest of the
cohort who have leaky splice site mutations or mutations in
the initiator methionine codon. There were statistically sig-
niﬁcant differences in overall severity (p = 0.0256; odds ratio
[OR] conﬁdence interval [CI] = [0.0265, 0.7901]) and age
at ﬁrst wheelchair use (p = 0.0012; CI = [0.2694, 1.0926]),
and they were more likely to have normal eye movements
(p = 0.0011; OR CI = [0.0333, 0.4315]). These individuals
were also more likely to have a malignancy (p = 0.0389),
with an odds ratio of 4.94 (OR CI = [1.0849, 22.5292])
compared with the rest of the cohort (see Fig 3;
Supplementary Table 3 and Supplementary Table 2).
Although there were no statistically signiﬁcant differ-
ences in neurological group, it is striking that predomi-
nant extrapyramidal signs were only observed in patients
with missense mutations (Group 2 and patient 50).
Individuals with a high ATM protein level had lower
AFP levels (p = 0.0235; CI = [–1.7628, –0.1270]), and slightly
higher A-T NEST scores (p = 0.0319; CI = [0.0713, 1.5825]).
FIGURE 3: (A) Graph shows number of individuals in each neurological phenotypic group in patients with retained ATM kinase activity
attributed to a missense mutation or a leaky splice-site mutation. (B) Graph shows numbers of individuals who use a wheelchair or are
still ambulant in patients with retained ATM kinase activity due to a missense mutation or a leaky splice-site mutation. (C) Graphs
shows cross-sectional clinical neurological disease severity in patients with retained ATM kinase activity attributed to a missense
mutation or a leaky splice-site mutation. (D) Graph shows number of malignancies diagnosed in patients with retained ATM kinase
activity attributed to a missense mutation or a leaky splice-site mutation. ATM = ataxia telangiectasia-mutated.
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There were no statistically signiﬁcant associations
between chromosomal radiosensitivity or number of mild
mutations with neurological or other clinical features.
Discussion
This study describes the largest published cohort of individ-
uals with variant ataxia-telangiectasia who have undergone
detailed genetic and clinical evaluation. We show that all
individuals included in this survey have neurological
involvement, while systemic features are mild or absent,
apart from an increased risk of malignancy.
Our study conﬁrms that disease severity in variant
ataxia-telangiectasia is milder compared to the classic
form. Our cohort includes 31 patients aged > = 40 years,
26% were still ambulant, 6 had children, and 11 were in
paid or voluntary employment. Consistent with other
reports,13 the majority of individuals included in this
study had their symptom onset in early childhood. How-
ever, disease progression is then much slower than in the
classic form.
We formally graded disease severity according to a
combination of neurological rating scales (A-T NEST,
SARA) and assessment of mobility and self-care. Accord-
ing to this grading, 32% of patients had mild disease and
only 19% severe disease. Similar to multiple sclerosis,
another multisystem neurological disease, we have chosen
to grade disease severity mainly according to functional
impairment and mobility.34 Further studies will be
required to validate our severity rating.
All individuals in our cohort showed neurological
abnormalities on clinical examination. A range of neuro-
logical systems were affected (cerebellum, peripheral
nerves, eye movements, and extrapyramidal system), but
none universally. For example, 10 individuals had no sig-
niﬁcant cerebellar features, 11 had normal eye movements,
and 8 had no evidence of peripheral nerve involvement. A
large proportion had extrapyramidal symptoms, and in
some, extrapyramidal presentation was the predominant
or only clinical feature. The most common extrapyramidal
symptoms were dystonia and dystonic tremor. Chorea and
parkinsonism were rare. Presence of exclusive extrapyrami-
dal symptoms has not been reported in classic A-T. This
suggests possible differences in neuronal vulnerability and
pathways between the classic and variant form of the dis-
ease and could be further explored with imaging studies.
With the limitation of small sample size, our study
suggests that disease severity is milder in individuals with
a purely extrapyramidal presentation compared to those
who have ataxia. This ﬁnding could partly reﬂect effective
treatments (botulinum toxin, medication, and deep brain
stimulation) for extrapyramidal symptoms. Longitudinal
studies will be important in order to evaluate whether
individuals with exclusive extrapyramidal or cerebellar
symptoms eventually progress to develop a more mixed
presentation.
Our study is the ﬁrst to report on neurological
investigations in a large number of patients with variant
ataxia-telangiectasia. We found that cerebellar and vermian
atrophy was the most common imaging abnormality,
although 5 individuals had a normal cerebellar appearance.
Cerebral microhemorrhages were shown in 2 of 19 patients
whose scan included gradient echo and SWI and white mat-
ter abnormalities occurred in 7 of 23 patients. Reported
radiological ﬁndings in classic ataxia-telangiectasia include
cerebellar atrophy and multiple punctate hemosiderin
deposits, but in some individuals also very extensive white
matter abnormalities,35 which were speculated to represent
“edema from vascular leakage.”36 It is possible that that the
extracerebellar abnormalities we observed could represent an
earlier stage of a process that progresses more ﬂoridly in some
individuals with classic ataxia-telangiectasia.
Neurophysiology studies showed that most patients
tested had an axonal sensorimotor polyneuropathy (18 of
34); 3 had predominant anterior horn involvement, and
9 had a combination of both. Interestingly, neurophysiol-
ogy was normal in 4 included individuals, all of whom
had mild disease progression but otherwise a mixture of
associated neurological symptoms.
Our study conﬁrms that the risk of malignancy is
signiﬁcantly increased in variant ataxia-telangiectasia. The
cancers in our cohort were predominantly female preme-
nopausal breast cancer and hematological malignancies.
There were only two childhood tumors, which is consis-
tent with Reiman’s study24 which showed a protective
effect of retained ATM kinase activity against childhood
tumors.
Individuals with a missense mutation which causes
production of a mutant ATM protein with retained kinase
activity were approximately 5 times more likely to have a
malignancy than individuals in the other genetic groups.
It has been previously reported that a speciﬁc missense
mutation, c. 7271T > G, p.(Val2424Gly), causes a high
risk of breast cancer.16 Canadian Mennonites who were
homozygous for the c.6200 C > A (p. Ala2067Asp) mis-
sense mutation also showed a high risk of malignancy.14
This is consistent with the idea that speciﬁc missense
mutations cause a high risk of malignancy, which suggests
a possible gain of function mechanism.
We found that individuals with a missense mutation
have milder neurological features, as measured by overall
severity and A-T NEST score. These patients are more
likely to remain ambulant and more likely to have normal
eye movements.
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The 4 individuals (34, 42, 43, and 44) who have
borderline low/absent ATM kinase activity had more
severe neurological features, and 2 required gastrostomy
feeding. Patients with a mutation in the initiator methio-
nine were included because of the evidence of longevity in
some of these patients and that their cells express a low
level of N-terminally truncated ATM protein, although, as
it turns out, without measurable activity using the assay
described. A more sensitive assay would be helpful in
detecting differential low levels of ATM activity/signaling
associated with different ATM proteins. This may also be
true of some ATM missense mutations (eg, c.5228C > T;
p.(Thr1743Ile) where current assays do not detect any
activity associated with the expressed protein. It is possible
that there may be sufﬁcient activity retained to have some
positive clinical effect. Individuals (3, 4, 5, 16, 20, 22,
23a, 23b, 27, 31, and 32) with a high ATM level (around
50% or more) showed higher A-T NEST scores (less
severe disease) and lower AFP levels. Taken together, these
results indicate that the reduced severity of the neurologi-
cal features may reﬂect the level of ATM kinase activity,
which is consistent with the fact that classic ataxia-
telangiectasia (where ATM kinase is absent) generally
presents with a more severe phenotype than variant ataxia-
telangiectasia.
Each of the ﬁve sets of siblings included here showed
similar neurological features. For example, 3 affected sis-
ters all have ataxia together with peripheral neuropathy,
dystonic tremor, and essentially normal eye movements.
Three Dutch siblings all presented with resting tremor
and distal muscle weakness attributed to anterior horn cell
involvement.18 This similarity between siblings is consis-
tent with the fact that the neurological phenotype is partly
determined by shared “genetic background.” However, we
did not ﬁnd signiﬁcant genotype-phenotype association
with regard to neurological group in the cohort overall,
indicating an additional inﬂuence of shared environmental
factors or disease modifying genes.
Systemic complications were mild or absent, apart
from the increased risk of malignancy. This is consistent
with previous reports4,13,14 and has signiﬁcant implications
on surveillance and management of these patients. None of
the individuals in this study had signiﬁcant respiratory dis-
ease. Functional testing with arterial blood gases and over-
night oximetry was essentially normal. Even though 42 of
53 tested individuals had a detectable abnormality on
immunological testing, in general this was subtle and of
doubtful clinical signiﬁcance. No individual required treat-
ment with immunoglobulin replacement, and only 2 used
prophylactic antibiotics for recurrent pulmonary infections.
Our cohort includes only 2 patients with diabetes mellitus,
which suggests a similar prevalence to in the general
population. However, more than one quarter of included
individuals had abnormalities in their liver function tests,
the relevance of which needs to be further investigated in
future studies.
Our results suggest that variant ataxia-telangiectasia
is likely to be under- or misdiagnosed. The time from ﬁrst
symptoms to diagnosis was over 10 years in more than
half of our cohort, and we included individuals with only
very mild neurological symptoms. Clinicians may not be
familiar with the wide range of clinical presentations of
variant ataxia-telangiectasia, where eye movements can be
normal, conjunctival telangiectasia absent, neurological
presentation mainly extrapyramidal, and AFP levels within
normal range.
Individuals with variant ataxia-telangiectasia require
surveillance for malignancy and management guidance—
including breast screening in women, minimising exposure
to ionising radiation and facilitating specialist assessments.
Missense mutations are associated with milder neurological
presentations, but have a particularly high malignancy risk,
and it is important for clinicians to be aware of these
phenotypes.
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